MPscore: A Novel Predictive and Prognostic Scoring for Progressive Meningioma

Area of Science:

• Neuro-oncology
• Genomics
• Cancer Biology

Background:

• Meningioma is the most common central nervous system (CNS) tumor, with most cases being benign but some posing therapeutic challenges due to recurrence.
• Tumor heterogeneity necessitates subtyping for better diagnosis and treatment strategies.
• DNA methylation profiling indicates significant molecular diversity within meningiomas.

Purpose of the Study:

• To characterize progressive features of meningioma through clustering analyses.
• To identify distinct meningioma subtypes based on transcriptomic data.
• To develop and validate a meningioma progression score (MPscore) for predicting recurrence risk.

Main Methods:

• Transcriptome sequencing data from 179 meningioma samples were analyzed using clustering.
• Copy number alterations, DNA methylation, and immune cell infiltration were characterized for each subtype.
• A meningioma progression score (MPscore) was constructed using signature genes from the progressive subtype and validated in independent cohorts.

Main Results:

• Four biologically distinct meningioma subtypes were identified, with subtype 3 enriched in aggressive tumors (anaplastic and atypical meningiomas).
• Subtype 3 showed higher infiltration of CD8-positive T cells, indicating a distinct immune microenvironment.
• The validated MPscore demonstrated predictive accuracy and prognostic capacity for meningioma recurrence.

Conclusions:

• The study uncovers four distinct molecular subtypes of meningioma, offering new insights into tumor biology.
• The MPscore is a promising tool for predicting meningioma recurrence risk and guiding treatment stratification.
• Further research into these subtypes could lead to more targeted and effective therapeutic strategies for challenging meningioma cases.